News Release
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Alan H. Auerbach - Los Angeles Business Journal
Here's Why Puma Biotechnology Fell 17.2% in April | The Motley Fool
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
PumaBiotech on Twitter: "Puma Biotechnology is dedicated to developing innovative, new treatments to help #cancer patients. As part of our ongoing commitment to the cancer community, we're proud to have participated in #
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Puma (PBYI): Recent Rally Looks Overdone, Unsupported With Fundamentals | Seeking Alpha
Puma Biotechnology falls more than 20%
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology Inc
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
PumaBiotech (@pumabiotech) / Twitter
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma shares nearly triple on drug news, but options smell 'fishy'
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
